We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Controlling the Transient Activation of Protein Kinases in Living Cells

By LabMedica International staff writers
Posted on 27 Dec 2016
Print article
Image: The molecular model of tyrosine kinase c-Src (Src) (Photo courtesy of Wikimedia Commons).
Image: The molecular model of tyrosine kinase c-Src (Src) (Photo courtesy of Wikimedia Commons).
The study of the effects of protein kinase enzymes in living cells has been enhanced by the development of a technique to control when and for how long a specific kinase is active.

Protein kinases, which transfer phosphate from the energy molecule ATP to other enzymes and proteins, are involved in almost every biological process. While significant progress has been made in defining the role of many kinases, understanding how specific kinases orchestrate complex signaling events remains challenging.

Investigators at the University of Illinois, Chicago (USA) have described a method to control the timing and the duration of kinase activity. This system provides the ability to mimic physiologically relevant transient activation of a kinase.

They reported in the December 12, 2016, online edition of the journal Proceedings of the [U.S.] National Academy of Sciences that by using two protein-engineering approaches, they could achieve independent control of kinase activation and inactivation. They demonstrated successful regulation of tyrosine kinase c-Src (Src) and Ser/Thr kinase p38alpha (p38), demonstrating the broad applicability of the method. By using this approach, they identified morphological changes induced by transient activation of Src and demonstrated the role of sequential Src-PI3K (Phosphoinositide 3-kinase) and Src-Rac1 (Ras-related C3 botulinum toxin substrate 1) signaling in regulation of cell morphology.

"Previously, we had the ability to artificially turn on a kinase, but we did not know how to turn it off," said senior author Dr. Andrei Karginov, assistant professor of pharmacology in the University of Illinois, Chicago. "So what we could see was only the result of that kinase being on for a long time. But, in living cells, kinases are often turned only for a set period of time, and the duration of this activation often dictates what will happen to the cell. To mimic this transient action we had come up with a new strategy."

Related Links:
University of Illinois, Chicago

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Liquid biopsy could detect and monitor aggressive small cell lung cancer (Photo courtesy of Shutterstock)

Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a highly aggressive type of cancer known for its ability to metastasize. The behavior of tumors is largely governed by which genes are turned on, or transcribed, irrespective... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.